One-arm, single-center, open-label clinical study of concurrent chemoradiotherapy combined with adjuvant chemotherapy and antiangiogenic therapy for advanced malignant tumors
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Rivoceranib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 10 Aug 2018 New trial record